Theratechnologies Book/Share
What is the Book/Share of Theratechnologies?
The Book/Share of Theratechnologies Inc. is 0.16
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Theratechnologies
What does Theratechnologies do?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
Companies with book/share similar to Theratechnologies
- China City Infrastructure has Book/Share of 0.16
- Healthcare Merger has Book/Share of 0.16
- FinServ Acquisition Corp has Book/Share of 0.16
- Sezzle has Book/Share of 0.16
- ZincX Resources has Book/Share of 0.16
- Dingdong (Cayman) Ltd has Book/Share of 0.16
- Theratechnologies has Book/Share of 0.16
- Vivos Therapeutics has Book/Share of 0.16
- Tritent International has Book/Share of 0.16
- Garibaldi Resources has Book/Share of 0.16
- Fujian has Book/Share of 0.16
- Nova Minerals has Book/Share of 0.16
- Kwan Yong has Book/Share of 0.16